Hereditary Cancer was Myriad Genetics’s largest product and service line in fiscal 2025, bringing in $327.80M of $768.00M (43%).
| Product and Service | FY 2013 | FY 2015 | FY 2016 | FY 2016 | FY 2016 | FY 2017 | FY 2017 | FY 2017 | FY 2017 | FY 2018 | FY 2018 | FY 2018 | FY 2018 | FY 2019 | FY 2019 | FY 2019 | FY 2020 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Diagnostic - Hereditary Cancer Testing | — | — | — | — | |||||||||||||||||
| Bracanalysis | — | — | — | — | |||||||||||||||||
| Molecular Diagnostic Testing | — | — | — | — | |||||||||||||||||
| Molecular Diagnostic Revenues | — | — | — | — | |||||||||||||||||
| Prenatal | $115.60M | $301.90M | $353.60M | $186.30M | |||||||||||||||||
| Hereditary Cancer | $263.50M | $47.30M | $45.90M | $327.80M | |||||||||||||||||
| Tumor Profiling | $84.50M | $237.70M | $230.00M | $109.80M | |||||||||||||||||
| Mental Health | — | $138.50M | $170.20M | $144.10M | |||||||||||||||||
| Pharmacogenomics | $127.60M | — | — | — | |||||||||||||||||
| Other | — | — | — | — | |||||||||||||||||
| Molecular Diagnostic - Genesight | — | — | — | — | |||||||||||||||||
| Molecular Diagnostic- Vectra | — | — | — | — | |||||||||||||||||
| Pharmaceutical & Clinical Services | — | — | — | — | |||||||||||||||||
| Molecular Diagnostic - Prolaris | — | — | — | — | |||||||||||||||||
| Molecular Diagnostic - Other | — | — | — | — | |||||||||||||||||
| Molecular Diagnostic - Endopredict | — | — | — | — | |||||||||||||||||
| Autoimmune | $300.00K | — | — | — | |||||||||||||||||
| Total | $591.50M | $725.40M | $799.70M | $768.00M |
Myriad Genetics brought in $768.00M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 4.0% from $799.70M in fiscal 2024. Hereditary Cancer was the largest at $327.80M (42.7%), ahead of Prenatal at $186.30M (24.3%) and Mental Health at $144.10M (18.8%). The remaining line, Tumor Profiling, brought in $109.80M.
Compared with fiscal 2024, Hereditary Cancer grew fastest, up 614.2% to $327.80M, while Tumor Profiling fell the most, down 52.3% to $109.80M.
Myriad Genetics began breaking out Mental Health in fiscal 2023, when it brought in $138.50M. Myriad Genetics stopped reporting Pharmacogenomics ($127.60M in fiscal 2022) and Autoimmune ($300.00K in fiscal 2022) as separate lines.
U.S was Myriad Genetics’s largest region in fiscal 2025, bringing in $327.80M of $372.40M (88%).
| Geography | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| U.S | — | $280.50M | $318.60M | $327.80M | |||
| United States | $263.50M | — | — | — | |||
| Row | — | $47.30M | $45.90M | $44.60M | |||
| Rest Of World | $44.10M | — | — | — | |||
| Total | $307.60M | $327.80M | $364.50M | $372.40M |
Myriad Genetics brought in $372.40M from its two regions in fiscal 2025, the year ended December 31, 2025. That is less than the $768.00M it reports by product and service, so these regions do not cover all of its revenue. U.S was the largest at $327.80M (88.0%), ahead of Row at $44.60M (12.0%).
Compared with fiscal 2024, U.S grew 2.9% to $327.80M, while Row fell 2.8% to $44.60M.
Myriad Genetics began breaking out U.S in fiscal 2023 and Row in fiscal 2023. Myriad Genetics stopped reporting United States ($263.50M in fiscal 2022) and Rest Of World ($44.10M in fiscal 2022) as separate regions.
As Reported was Myriad Genetics’s largest revenue line in fiscal 2017, bringing in $185.20M of $183.00M (101%).
| Restatement | FY 2015 | FY 2016 | FY 2016 | FY 2016 | FY 2017 |
|---|---|---|---|---|---|
| As Reported | $695.50M | $705.70M | $165.10M | $183.90M | $185.20M |
| Adjustment | -$600.00K | -$13.30M | $1.40M | $200.00K | -$2.20M |
| Total | $694.90M | $692.40M | $166.50M | $184.10M | $183.00M |
Myriad Genetics brought in $183.00M from its two revenue lines in fiscal 2017, the year ended March 31, 2017. That was down 0.6% from $184.10M in fiscal 2016. As Reported was the largest at $185.20M (101.2%).
From fiscal 2015 to 2017, combined revenue from these revenue lines fell from $694.90M to $183.00M, a compound annual decline of 48.7%. As Reported's share of the total rose from 100.1% to 101.2%.
The total is net of Adjustment, which took $2.20M off revenue in fiscal 2017.
Myriad Genetics (MYGN) reports its revenue by product and service, by geography and by restatement. In fiscal 2025, Hereditary Cancer was its largest product and service line, bringing in $327.80M (42.7% of the total), followed by Prenatal at $186.30M (24.3%).
Hereditary Cancer was Myriad Genetics' largest product and service line in fiscal 2025, bringing in $327.80M, or 42.7% of the $768.00M total across its four product and service lines.
U.S was Myriad Genetics' largest region in fiscal 2025, bringing in $327.80M, or 88.0% of the $372.40M total across its two regions.
As Reported was Myriad Genetics' largest revenue line in fiscal 2017, bringing in $185.20M, or 101.2% of the $183.00M total across its two revenue lines.
Among Myriad Genetics' product and service lines that make up at least 2% of revenue, Hereditary Cancer grew fastest in fiscal 2025, up 614.2% from $45.90M to $327.80M.
Every figure comes from Myriad Genetics' annual financial filings, as reported. Each line keeps the name Myriad Genetics gives it, and years follow its fiscal calendar.
Myriad Genetics' revenue by product and service goes back to fiscal 2013, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.